title: Pharmacogenetics: Anti-TNF therapy in RA--towards personalized medicine?
abstract: A substantial proportion of patients with rheumatoid arthritis do not respond to tumor necrosis factor blocking therapy. Results of a large genome-wide association study demonstrate evidence of novel genetic factors that determine response to treatment, which could provide a basis for individualizing therapy.
authors.affiliation: Departments of Pathology and Rheumatology, Section of Inflammatory Disease Profiling, VU University Medical Center, Amsterdam, The Netherlands. c.verweij@vumc.nl
authors.forename: Cornelis L
authors.initials: CL
authors.lastname: Verweij
mesh_terms: D048868:Adaptor Proteins, Signal Transducing / Q000235:genetics; D001172:Arthritis, Rheumatoid / Q000188:drug therapy*; D015815:Cell Adhesion Molecules; D006801:Humans; D009363:Neoplasm Proteins / Q000235:genetics; D010597:Pharmacogenetics / Q000639:trends*; D020641:Polymorphism, Single Nucleotide / Q000235:genetics; D057285:Precision Medicine / Q000639:trends*; D015534:Trans-Activators / Q000235:genetics; D016896:Treatment Outcome; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*
chemical_list: D048868:Adaptor Proteins, Signal Transducing; D015815:Cell Adhesion Molecules; C117736:EYA4 protein, human; D009363:Neoplasm Proteins; C423943:PDZD2 protein, human; D015534:Trans-Activators; D014409:Tumor Necrosis Factor-alpha